Literature DB >> 7907862

Somatostatin: physiology and clinical applications.

A Shulkes1.   

Abstract

Somatostatin (SOM) was originally isolated as the hypothalamic inhibitor of growth hormone release but was subsequently shown to have a widespread distribution including the gastrointestinal tract. In fact the gastrointestinal tract contains about 70% of the total body SOM. SOM has inhibitory actions on gastrointestinal exocrine and endocrine secretions, motility and blood flow. Within the gut it functions as an endocrine, paracrine, autocrine and neurocrine factor. SOM is released by a meal, and a number of neurotransmitters and regulatory peptides also influence SOM release. SOM is a key component of the gastrin-acid feedback loop as luminal acid releases SOM, which in turn has inhibitory effects on both gastrin and gastric acid. Consistent with the diverse functions of SOM, a number of different although related SOM receptors with distinct distribution patterns and intracellular mediators have been cloned and sequenced. SOM is the first of the gut regulatory peptides to have a significant therapeutic use. By inhibiting both the target cell (e.g. parietal cell) and the release of the active agent (e.g. gastrin) the therapeutic potential of SOM is magnified. To date most of the clinical experience has been with the one analogue, octreotide. This analogue has a longer half-life than SOM (hours versus minutes) but has only minimal oral activity, therefore requiring subcutaneous injections several times a day. The definite gastrointestinal applications include treatment of gastroenteropancreatic tumours. It is also becoming a favoured treatment for gastrointestinal fistulae, variceal bleeding and diarrhoea. However, octreotide has no consistent effect on tumour growth. The high density of SOM receptors on tumours has allowed localization of tumours using in vivo scintography with labelled octreotide. The sequencing of a variety of SOM receptors with different distributions and differing cellular effector systems raises the likelihood of developing SOM analogues for specific clinical applications.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7907862     DOI: 10.1016/s0950-351x(05)80232-0

Source DB:  PubMed          Journal:  Baillieres Clin Endocrinol Metab        ISSN: 0950-351X


  11 in total

1.  Abdominal surgery inhibits circulating acyl ghrelin and ghrelin-O-acyltransferase levels in rats: role of the somatostatin receptor subtype 2.

Authors:  Andreas Stengel; Miriam Goebel-Stengel; Lixin Wang; Almaas Shaikh; Nils W G Lambrecht; Jean Rivier; Yvette Taché
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-06-02       Impact factor: 4.052

2.  Stimulation of somatostatin secretion by 3-O-methylglucose in the perfused dog pancreas.

Authors:  K Hermansen; S Lindskog; B Ahrén
Journal:  Int J Pancreatol       Date:  1996-10

3.  Somatostatin in gastroenterology.

Authors:  A Shulkes; J S Wilson
Journal:  BMJ       Date:  1994-05-28

4.  Cholecystokinin (CCK) regulates somatostatin secretion through both the CCK-A and CCK-B/gastrin receptors in sheep.

Authors:  Y Zavros; A Shulkes
Journal:  J Physiol       Date:  1997-12-15       Impact factor: 5.182

5.  The role of somatostatin (octreotide) in the regulation of melatonin secretion in healthy volunteers and in patients with primary hypothyroidism.

Authors:  J Wikner; L Wetterberg; S Röjdmark
Journal:  J Endocrinol Invest       Date:  1999 Jul-Aug       Impact factor: 4.256

Review 6.  Brain peptides and the modulation of postoperative gastric ileus.

Authors:  Andreas Stengel; Yvette Taché
Journal:  Curr Opin Pharmacol       Date:  2014-07-09       Impact factor: 5.547

7.  Plasma somatostatin-like immunoreactivity and somatostatin-28 levels in obese men.

Authors:  M Peracchi; F Carola; F Cavagnini; R Benti; B Bareggi; G Baccalaro; G Basilisco
Journal:  J Endocrinol Invest       Date:  1998-01       Impact factor: 4.256

8.  Somatostatin in inflammatory bowel disease.

Authors:  J D van Bergeijk; J H Wilson
Journal:  Mediators Inflamm       Date:  1997       Impact factor: 4.711

Review 9.  Gastrointestinal neuroendocrine peptides/amines in inflammatory bowel disease.

Authors:  Magdy El-Salhy; Tefera Solomon; Trygve Hausken; Odd Helge Gilja; Jan Gunnar Hatlebakk
Journal:  World J Gastroenterol       Date:  2017-07-28       Impact factor: 5.742

Review 10.  Somatostatin as an Active Substance in the Mammalian Enteric Nervous System.

Authors:  Slawomir Gonkowski; Liliana Rytel
Journal:  Int J Mol Sci       Date:  2019-09-10       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.